An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination with Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma - Regional Cancer Care Associates LLC

Clinical Trials

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination with Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma

Type of Cancer
Lymphoma
Locations
Bethesda
Sponsor
Protocol Number
INCB 50465-102
Cancer Diagnosis
To Learn More Call
201-510-0910